Adenosine deaminase acting on RNA1 mutation in chilblain lupus treated with tofacitinib

Read full text Summarise with VIRAT
Authors: Alexander T. Velaoras, Sabah Iqbal, Alex Silberzweig, Kelly M Frasier, Silvija P. Gottesman, CYNTHIA M.J. MAGRO, Sheila Shaigany
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Familial chilblain lupus (FCL) is a rare form of monogenic cutaneous lupus presenting in childhood with recurrent, cold-induced, painful violaceous papules at acral sites oftentimes with concomitant inflammatory arthritis, Raynaud’s phenomenon, and cytopenias. As a variant of lupus erythematosus, immunofluorescent testing of lesional skin will show a positive lupus band test. FCL commonly arises from de novo mutations involving interferonopathy-related genes such as 3 prime repair exonuclease 1 (TREX1) and stimulator of interferon genes (STING), subsequently causing overactivated type-I interferon (IFN-I) signaling and autoinflammation.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Dermatological and COVID-19 studies Systemic Sclerosis and Related Diseases

Publication details

Journal / source
JAAD Case Reports
Volume
72
Pages
31–34
Publication date
31 March 2026
Language
EN